A Prospective Cohort Study to Evaluate Molecular pRognostic Factors and Resistance Mechanisms to Osimertinib in Adjuvant Treatment of Completely Resected pIB-IIIA Non-small Cell Lung Carcinoma With Common EGFR Mutations (L858R and Del19)

Clinical trial NCT06053099 · RECRUITING

Trial details

NCT number: NCT06053099
Sponsor: Intergroupe Francophone de Cancerologie Thoracique
Status: RECRUITING
Phase: Not Applicable
Study type: INTERVENTIONAL

Non Small Cell Lung Cancer EGFR Activating Mutation EGFR DEL19 EGFR L858R

Start date: 2024-01-22
Primary completion: 2031-10-01
Enrollment: 300

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.